VIVE - Viveve Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.76
-0.15 (-5.15%)
At close: 4:00PM EDT

2.76 0.00 (0.00%)
After hours: 4:43PM EDT

Stock chart is not supported by your current browser
Previous Close2.91
Open3.01
Bid2.70 x 2200
Ask3.10 x 1000
Day's Range2.55 - 3.03
52 Week Range1.60 - 8.17
Volume732,631
Avg. Volume564,115
Market Cap86.304M
Beta1.48
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.44
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Viveve Reports Positive Six-Month Data from Stress Urinary Incontinence Feasibility Study

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today reported positive and sustained six-month data from an ongoing single-arm feasibility study using its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform for the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. The ongoing study is being conducted by Bruce Allan, PhD, MD, FRCS(C), founder and medical director of the Allan Centre in Calgary, Alberta. “These new data are extremely encouraging for women suffering from stress urinary incontinence, further validating the positive 12-month SUI pilot study data that we reported in February.

  • GlobeNewswire18 days ago

    Viveve Announces Settlement of Patent Infringement Litigation with Thermi

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that is has reached a settlement to resolve the patent litigation that it filed in 2016 against ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red Alinsod in the U.S. District Court for the Eastern District of Texas citing infringement of Viveve’s intellectual property (Viveve, Inc. v. ThermiGen, LLC, No.2:16-1189). Under the settlement, Viveve will receive a monetary payment and on-going royalty, as well as other mutual agreements relating to certain intellectual property owned by the companies.

  • GlobeNewswire24 days ago

    Viveve to Present at Jefferies Global Healthcare Conference

    Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single 30-minute in-office session.

  • Zacks Small Cap Researchlast month

    VIVE: Q1 Results: Disappointing But Not All Was Bad. Guidance Intact But That May Now Be More Challenging

    Viveve (VIVE) reported Q1 2018 financial results and provided a business update. Despite what we’d characterize as a pretty disappointing start to the year, management reiterated their previously issued 2018 revenue guidance in the range of $22M (+44%) to $24M (+57%). VIVE indicated that realignment of the sales force/territories and a national sales meeting (which sidelined the entire sales force for a week) significantly impacted Q1 domestic sales results.

  • GlobeNewswirelast month

    Viveve Announces Initiation of VIVEVE II Clinical Study

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that patient enrollment is underway in the multicenter randomized VIveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical study to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. As a result, we anticipate submitting the 30-day safety data from the first 25 treated patients to the FDA for review by the end of the second quarter,” said Scott Durbin, chief executive officer of Viveve.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of VIVE earnings conference call or presentation 10-May-18 9:00pm GMT

    Q1 2018 Viveve Medical Inc Earnings Call

  • GlobeNewswirelast month

    Viveve Reports First Quarter 2018 Financial Results

    Continued quarter-over-quarter annual revenue growth and rapid expansion into stress urinary incontinence market planned for Viveve ® System. ENGLEWOOD, Colo., May 10, 2018-- Viveve Medical Inc., a medical ...

  • GlobeNewswirelast month

    Viveve Appoints Scott Durbin as Chief Executive Officer

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin has been appointed as the company’s Chief Executive Officer, effective immediately. Mr. Durbin, a seasoned healthcare executive and the company’s former Chief Financial Officer, will also join the Board of Directors. Mr. Durbin’s appointment follows Patricia Scheller’s decision to step down from her position as Chief Executive Officer to pursue other personal and business opportunities.

  • GlobeNewswire2 months ago

    Viveve to Announce First Quarter 2018 Financial Results

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced it will report financial results for the first quarter ended March 31, 2018 on Thursday, May 10, 2018 after the close of the U.S. financial markets. The company will also host a live conference call and webcast to discuss these financial results and provide an update on corporate and commercial developments. Participating on the call will be Patricia Scheller, chief executive officer and director, Scott Durbin, chief financial officer, and James Atkinson, chief business officer and president.

  • Zacks Small Cap Research3 months ago

    VIVE: Q4 Results: 108% Sales Growth in Q4. 2018 Catalysts Include Doubling+ Sales Force, SUI-Related Adoption, VIVEVE II

    The business update encompassed several near-term goals including further significant growth of the direct sales force, regulatory approval and entry into additional territories, progress towards label expansion, introduction of complementary products and continued strong revenue and margin growth. Just days after the Q4 earnings announcement, VIVE received notice that FDA approved their IDE to conduct ‘VIVEVE II’, the clinical trial which is expected to serve as primary support for an eventual U.S. regulatory filing seeking clearance for a ‘sexual-function’ related indication. While very long-in-the-tooth, the IDE approval was welcome news as it means that Geneveve could relatively soon be the only energy-based technology cleared by FDA for such an indication.

  • Marketwired3 months ago

    Viveve Announces FDA Approval of IDE to Conduct VIVEVE II Clinical Study

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced it received approval of its Investigational Device Exemption application from the U.S. Food and Drug ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of VIVE earnings conference call or presentation 15-Mar-18 9:00pm GMT

    Q4 2017 Viveve Medical Inc Earnings Call

  • Colorado women's sexual health company expanding; Q4, 2017 revenues rise
    American City Business Journals3 months ago

    Colorado women's sexual health company expanding; Q4, 2017 revenues rise

    The company makes medical treatment for vaginal laxity, which occurs primarily after childbirth.

  • Marketwired3 months ago

    Viveve Reports Fourth Quarter and Full Year 2017 Financial Results

    Viveve Medical Inc. , a medical technology company focused on women's intimate health, today reported financial results for the three months and year ended December 31, 2017."Our successful fourth-quarter ...

  • Marketwired3 months ago

    Viveve to Announce Financial Results for Fourth Quarter and Year End 2017

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, will announce financial results for the fourth quarter and the full year ended December 31, 2017 on Thursday, March ...

  • Marketwired4 months ago

    Viveve to Present at March Investor Conferences

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced that Patricia Scheller, chief executive officer and director, will present an update on the company's ...

  • Marketwired4 months ago

    Viveve to Participate in BTIG Healthcare Conference

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief financial officer, will participate in the 2018 BTIG Healthcare Conference, ...

  • Marketwired4 months ago

    Viveve Announces Closing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its ...

  • Marketwired4 months ago

    Viveve to Present at Leerink Global Healthcare Conference

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced that Patricia Scheller, chief executive officer and director, will present at the 2018 Leerink Global ...

  • Zacks Small Cap Research4 months ago

    VIVE: SUI Indication Could Further Enhance Marketing Message, Drive Adoption

    According to the National Association for Incontinence, SUI affects approximately 15M American women and approximately 200M people across the globe suffer from some form of urinary incontinence.  SUI, or urinary leakage associated with physical movements (such as coughing, sneezing or running), is a relatively common condition among women that have had children.  Similar to vaginal laxity, SUI is also a result of a weakening of pelvic muscles, including those that support the bladder.

  • Marketwired4 months ago

    Viveve Announces Pricing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public ...

  • Marketwired4 months ago

    Viveve Announces Proposed Public Offering of Shares of Common Stock

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of ...

  • Marketwired5 months ago

    Viveve Announces Expansion of CMRF Technology Platform into Stress Urinary Incontinence Market

    Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced the expansion of its cryogen-cooled, monopolar radiofrequency technology platform into the stress ...

  • Zacks Small Cap Research6 months ago

    VIVE: Q4 2017 Preannouncement, Full-Year 2018 Initial Guidance Largely Inline With Our Estimates

    This morning Viveve (VIVE) announced preliminary unit and consumables sales numbers as well as revenue for the fourth quarter 2017 and provided initial revenue guidance for the full-year 2018, most of which was largely inline with our respective estimates.

  • Marketwired6 months ago

    Viveve Announces Preliminary 2017 Fourth Quarter and Year-End Financial Results and Provides 2018 Revenue Guidance

    Viveve Medical Inc. , a medical technology company focused on women's health and wellness, today reported preliminary financial results for the three months and full year ended December 31, 2017."Viveve ...